-
公开(公告)号:US20110287437A1
公开(公告)日:2011-11-24
申请号:US12713962
申请日:2010-05-20
申请人: Hans Marcus Ludwig Bitter , Kyle Louis Kolaja , Preeti Dhawan , Hirdesh Uppal , Rama Rajaraja Varma
发明人: Hans Marcus Ludwig Bitter , Kyle Louis Kolaja , Preeti Dhawan , Hirdesh Uppal , Rama Rajaraja Varma
CPC分类号: G01N33/5047 , G01N33/5014 , G01N2500/10
摘要: The likelihood that a compound will exhibit cardiotoxicity in vivo can be predicted using a model of in vitro assays performed on primary human cardiomyocytes.
摘要翻译: 可以使用在原代人心肌细胞上进行的体外测定的模型来预测化合物在体内显示心脏毒性的可能性。
-
公开(公告)号:US20110212461A1
公开(公告)日:2011-09-01
申请号:US12713976
申请日:2010-02-26
CPC分类号: C12Q1/485 , G01N2500/00
摘要: The likelihood that a compound will exhibit cardiotoxicity in an in vitro or in vivo assay predicted by the ability of the compound to inhibit at least one kinase from a selected group.
摘要翻译: 化合物在通过化合物抑制来自所选组的至少一种激酶的能力的体外或体内测定中显示心脏毒性的可能性。
-
公开(公告)号:US20110212480A1
公开(公告)日:2011-09-01
申请号:US12713985
申请日:2010-02-26
申请人: Kyle Louis Kolaja , Preeti Dhawan , Hirdesh Uppal
发明人: Kyle Louis Kolaja , Preeti Dhawan , Hirdesh Uppal
IPC分类号: C12Q1/02
CPC分类号: G01N33/5061
摘要: The present invention provides for the use of primary human cardiomyocytes for the testing of agents that have cardiotoxic effects and other modulatory effects on the heart.
摘要翻译: 本发明提供了使用原代人心肌细胞来测试对心脏具有心脏毒性作用和其它调节作用的药剂。
-
-